Compare SUPN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUPN | RCKT |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 340.9M |
| IPO Year | 2012 | N/A |
| Metric | SUPN | RCKT |
|---|---|---|
| Price | $47.22 | $3.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $63.25 | $29.12 |
| AVG Volume (30 Days) | 664.8K | ★ 2.3M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $681,539,000.00 | N/A |
| Revenue This Year | $8.32 | N/A |
| Revenue Next Year | $23.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.54 | N/A |
| 52 Week Low | $29.16 | $2.19 |
| 52 Week High | $57.65 | $13.50 |
| Indicator | SUPN | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 52.07 |
| Support Level | $45.36 | $3.30 |
| Resistance Level | $47.26 | $3.65 |
| Average True Range (ATR) | 1.23 | 0.19 |
| MACD | 0.36 | 0.05 |
| Stochastic Oscillator | 92.10 | 66.22 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.